SLU-PP-332
Exercise mimetic that activates endurance pathways, improves mitochondrial function, increases fat burning, and boosts muscle endurance — without actual exercise.
Key Facts
- ClassificationCapsule — Exercise mimetic that activates endurance pathways without working out.
- Primary BenefitsFat Loss (7/10) · Muscle Growth (6/10) · Longevity (6/10)
- AdministrationOral
- Typical Dose10-50 mg by mouth daily. This is a research compound, so dosing protocols are still being figured out.
- Evidence StrengthAnecdotal — 20 peer-reviewed studies referenced · Community sentiment 8/10
- Stacks Well WithMOTS-c, SS-31
- Legal StatusResearch Use Only · not prescribable in US
Quick Facts
- From price
- $70
- Type
- capsule
- Administration
- Oral
- Evidence
- anecdotal
- Studies referenced
- 20
- Community sentiment
- 8/10
- Stacks with
- 2 peptides
- Regulatory
- Research Use Only
Top benefits
Dosing
10-50 mg by mouth daily. This is a research compound, so dosing protocols are still being figured out.
Benefit Profile
| Vendor | Variant | Price | |
|---|---|---|---|
| Swiss Chems ⚠ FDA warning letter received late 2024 | 60ct 10mg | $69.95BEST | |
| Peptide Sciences ✕ Announced voluntary shutdown — stock availability may be limited or unavailable. Pricing data may be outdated. | 1g | $89.00 | Out of stock |
Stacks Well With
MOTS-c
Mitochondrial DNA-encoded peptide that activates AMPK, improving insulin sensitivity, fat burning, and mimicking exercise at the cellular level. Stacks well with SS-31 and NAD+.
SS-31 (Elamipretide)
Engineered to target inner mitochondrial membrane via cardiolipin binding. Stabilizes cristae, improves ATP production, and reduces oxidative stress. FDA-approved for Barth syndrome (as Forzinity) — the first FDA-approved mitochondria-targeted therapy.
Related 🔥 Fat Loss Peptides
Other peptides strong in fat loss
GLP-1 drug (Ozempic/Wegovy) that suppresses appetite and burns fat.
Tirzepatide10/10Dual GLP-1/GIP drug (Mounjaro/Zepbound). Strongest weight loss peptide available.
Retatrutide10/10Triple-action weight loss drug hitting GLP-1, GIP, and glucagon receptors.
CagriSema10/10Next-gen dual semaglutide + amylin analog with strongest weight loss data.
Survodutide9/10Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim.
Mazdutide9/10Dual GLP-1/glucagon receptor drug with strong weight loss results.